ARTICLE;
CANCER ADJUVANT THERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RECURRENCE;
CANCER STAGING;
CANCER SURVIVAL;
CLINICAL TRIAL;
COLON CANCER;
DISEASE FREE SURVIVAL;
DRUG EFFICACY;
HUMAN;
LUNG NON SMALL CELL CANCER;
MULTIPLE CYCLE TREATMENT;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
SURVIVAL TIME;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS, PHASE III AS TOPIC;
COLONIC NEOPLASMS;
DISEASE-FREE SURVIVAL;
FEMALE;
FLUOROURACIL;
FOLLOW-UP STUDIES;
HUMANS;
LEUCOVORIN;
MALE;
NEOPLASM RECURRENCE, LOCAL;
NEOPLASM STAGING;
ORGANOPLATINUM COMPOUNDS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
TIME FACTORS;
TREATMENT OUTCOME;
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial
Andre, T. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27, 3109-3116 (2009).
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials
Sargent, D. et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol. 23, 8664-8670 (2005).
End points for colon cancer adjuvant trials: Observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT group
Sargent, D. et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT group. J. Clin. Oncol. 25, 4569-4574 (2007).
Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials
Sargent, D. et al. Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol. 27, 872-877 (2009).
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07
Kuebler, J. et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J. Clin. Oncol. 25, 2198-2204 (2007).
A phase iii trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of the NSABP protocol C-07
Wolmark, N. et al. A phase iii trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of the NSABP protocol C-07. J. Clin. Oncol. 26 (Suppl.), 4005 (2008).
Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data on 12,676 patients from MOsAiC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803
Sargent, D. et al. Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data on 12,676 patients from MOsAiC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803. J. Clin. Oncol. 27, 4011 (2009).
